Qin, J.S et al. [38] suggested that ibrutinib or acalabrutinib intrinsically improved the potential of proliferation or the capacity of survival of CD19 CAR-T cells in CD19+ tumor cells and reduced the cytokine secretion; meanwhile, according to the tumor cell lines used in their experiment which are resistant to the growth inhibition mediated by BTK inhibitors, they thought that pharmacological function of CAR-T cells could be influenced by the efficacy of tumor cell biology mediated by BTK inhibitors. This evidence concerns the gene CD19 and neoplasm.